A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers.

Trial Profile

A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Cangrelor; Moxifloxacin
  • Indications Acute coronary syndromes; Coronary artery disease; Thromboembolism
  • Focus Adverse reactions
  • Sponsors The Medicines Company
  • Most Recent Events

    • 17 Jan 2012 Actual patient number is 67 according to ClinicalTrials.gov.
    • 15 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2011 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top